The global liquid biopsy market size was valued at USD 2269.81 billion in 2024, driven by the rising incidence of cancer cases across the globe. The market is expected to grow at a CAGR of 22.0% during the forecast period of 2025-2034, with the values likely to rise from USD 2769.17 billion in 2025 to USD 13591.48 billion by 2034. The increasing demand for non-invasive cancer diagnostic methods and advancements in liquid biopsy market technologies are key factors driving market growth.

Liquid Biopsy Market Overview
Liquid biopsy is a revolutionary diagnostic technique that detects cancer-related biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) from blood samples. It is a minimally invasive alternative to traditional tissue biopsies, offering advantages such as early cancer detection, real-time monitoring, and personalized treatment planning. The adoption of liquid biopsy is expanding across oncology, infectious diseases, and prenatal screening, contributing to its market growth.

Liquid Biopsy Market Dynamics
The liquid biopsy market is influenced by several key factors, including drivers, challenges, and emerging opportunities:

1. Drivers:

   • Rising Incidence of Cancer: The increasing prevalence of cancer worldwide is a major driver of the liquid biopsy market.

   • Technological Advancements in Liquid Biopsy: Innovations in next-generation sequencing (NGS) and polymerase chain reaction (PCR) are enhancing test accuracy.

   • Growing Demand for Non-Invasive Diagnostic Procedures: Liquid biopsies offer a painless and efficient alternative to traditional biopsies.

2. Challenges:

   • High Costs of Liquid Biopsy Tests: The cost of advanced liquid biopsy tests remains a challenge for widespread adoption.

   • Regulatory Complexities: Stringent approval processes for new liquid biopsy technologies can delay market entry.

3. Opportunities:

   • Expansion into Early Cancer Detection: Increasing investments in early-stage cancer diagnostics are opening new market avenues.

   • Integration of AI and Machine Learning: AI-powered liquid biopsy analysis is improving diagnostic accuracy and treatment personalization.

External Liquid Biopsy Market Trends

• Increasing Applications Beyond Oncology: Liquid biopsy is being explored for infectious diseases, organ transplant monitoring, and prenatal testing.

• Growth of Companion Diagnostics: Liquid biopsy is playing a crucial role in personalized cancer treatment and drug development.

• Expansion of Direct-to-Consumer Testing: The rise of at-home liquid biopsy kits is making cancer screening more accessible.

• Adoption of Multi-Omics Approaches: Combining liquid biopsy with proteomics and metabolomics is enhancing cancer detection capabilities.

Liquid Biopsy Market Segmentation
The liquid biopsy market is segmented based on biomarker type, technology, sample type, application, and end-user.

1. By Biomarker Type:

   • Circulating Tumor DNA (ctDNA)

   • Circulating Tumor Cells (CTCs)

   • Extracellular Vesicles (EVs)

   • Others

2. By Technology:

   • Next-Generation Sequencing (NGS)

   • Polymerase Chain Reaction (PCR)

   • Microarrays

   • Other Technologies

3. By Sample Type:

   • Blood

   • Urine

   • Plasma

   • Others

4. By Application:

   • Oncology (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Others)

   • Non-Oncology Applications (Infectious Diseases, Prenatal Testing, Organ Transplant Monitoring, Others)

5. By End-User:

   • Hospitals and Clinics

   • Diagnostic Laboratories

   • Academic and Research Institutions

   • Other End-Users

Liquid Biopsy Market Growth
The liquid biopsy market is experiencing rapid growth due to the increasing adoption of non-invasive cancer diagnostics, advancements in biomarker research, and the expanding role of liquid biopsy in precision medicine. The rise in awareness programs and government initiatives supporting cancer screening is also contributing to market expansion.

Get a Free Sample Report with a Table of Contents: https://www.expertmarketresearch.com/reports/liquid-biopsy-market/requestsample

Recent Liquid Biopsy Market Developments

• Launch of AI-Based Liquid Biopsy Solutions: AI-powered data analysis is enhancing the accuracy of liquid biopsy tests.

• Strategic Collaborations Between Biotech Firms: Partnerships are driving the development of next-generation liquid biopsy solutions.

• Regulatory Approvals for Liquid Biopsy Tests: Increasing FDA approvals are supporting the commercialization of innovative liquid biopsy technologies.

Liquid Biopsy Market Scope
The market scope includes applications in oncology, prenatal screening, and infectious disease diagnostics. With continuous advancements in technology and an increasing focus on precision medicine, the market is expected to expand further into new therapeutic areas. The adoption of liquid biopsy for treatment monitoring and early detection is expected to improve patient outcomes globally.

Liquid Biopsy Market Analysis
A comprehensive analysis of the liquid biopsy market highlights strong growth potential, driven by increasing cancer prevalence, expanding biomarker research, and technological innovations. The competitive landscape is evolving as key players invest in RD and strategic collaborations to enhance their market presence.

COVID-19 Impact Analysis
The COVID-19 pandemic disrupted healthcare services but also accelerated the demand for non-invasive diagnostic methods like liquid biopsy. The increased focus on telemedicine and remote patient monitoring further emphasized the value of liquid biopsy in personalized healthcare. Post-pandemic, the market continues to witness strong growth as healthcare providers integrate liquid biopsy into routine cancer screening and disease management strategies.

Key Players

1. ANGLE plc: Based in Surrey, UK, ANGLE plc specializes in liquid biopsy technology for cancer detection and treatment monitoring.

2. Oncimmune Holdings PLC: Headquartered in Nottingham, UK, Oncimmune focuses on early cancer detection using biomarker-based liquid biopsy solutions.

3. Guardant Health: Based in California, USA, Guardant Health is a leading provider of liquid biopsy tests for precision oncology.

4. Myriad Genetics, Inc.: Headquartered in Utah, USA, Myriad Genetics develops molecular diagnostic tests, including liquid biopsy solutions for cancer screening.

5. Biocept, Inc.: Based in California, USA, Biocept specializes in liquid biopsy tests for solid tumor cancers and central nervous system malignancies.

6. Lucence Health Inc.: Headquartered in Singapore, Lucence Health offers multi-cancer liquid biopsy solutions using advanced genomic sequencing technologies.

FAQ

1. What is liquid biopsy?
   Liquid biopsy is a non-invasive diagnostic method that detects cancer-related biomarkers in bodily fluids like blood and urine.

2. Why is the liquid biopsy market growing?
   The market is expanding due to the rising prevalence of cancer, advancements in biomarker research, and increased adoption of precision medicine.

3. Who are the key players in the liquid biopsy market?
   Major players include ANGLE plc, Oncimmune Holdings PLC, Guardant Health, Myriad Genetics, Biocept, and Lucence Health Inc.

4. How did COVID-19 impact the liquid biopsy market?
   The pandemic accelerated demand for non-invasive diagnostics, boosting liquid biopsy adoption in oncology and infectious disease management.

5. What are the major trends in liquid biopsy?
   Trends include AI integration, expansion beyond oncology, and the rise of direct-to-consumer liquid biopsy tests.

6. Which cancers are commonly detected using liquid biopsy?
   Liquid biopsy is widely used for lung, breast, colorectal, prostate, and other cancers.

7. What is the forecasted growth of the liquid biopsy market?
   The market is projected to grow at a CAGR of 22.0%, reaching USD 13591.48 billion by 2034.